2021年欧洲肿瘤内科学会年会（ESMO）将于9月16-21日以全球虚拟网络会议的形式隆重召开，作为欧洲乃至世界最负名盛名和最具影响力的肿瘤内科学术会议，每年都有来自全球160多个国家的25000多名肿瘤学专业人士参会。ESMO日程目前已经公布，共有18项最新研究成果将由中国学者（含港澳台）在口头报告专场（Proffered Paper session）和小型口头报告专场(Mini oral session)进行汇报。【肿瘤资讯】带您抢先一览这些值得关注的“中国好声音”！（以下排名不分先后）
Proffered Paper session
专场：Basic science
2O - Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties
大会发言：Baiyong Li (Zhongshan, China)
专场：Gastrointestinal tumours, non-colorectal
1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system
大会发言：齐长松教授 北京大学肿瘤医院
专场：Gastrointestinal tumours, colorectal 2
LBA22 - Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine Versus Chemoradiation with Capecitabine for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of A Multicenter Randomised, Open-label, Phase III Trial
大会发言：丁培荣教授 中山大学肿瘤防治中心
专场： Head and neck cancer, excl. thyroid
858O - Results of KEYNOTE-122: a phase 3 study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
大会发言：陈德章教授（Anthony T.C. Chan）中国香港中文大学威尔斯亲王医院-包玉刚爵士癌症中心（中国香港）
859O - Refining TNM Staging System for Epstein-Barr Virus-Related Nasopharyngeal Carcinoma: A Multicenter Cohort Study
大会发言：Wang-Zhong Li (Guangzhou, China）
专场：Haematological malignancies
825O - Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: results from a bridging registrational study
大会发言：Mingyuan Sun (Tianjin, China)
833O - A phase 1b study result of HMPL-689, a PI3Kδ inhibitor, in Chinese patients with relapsed/refractory lymphoma
大会发言：曹军宁教授 复旦大学附属肿瘤医院
LBA48 - DUBLIN-3 (BPI-2358-103): A Global Phase (Ph) 3 Trial with the Plinabulin/Docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC Patients (pts) with EGFR-wild type (wt) Progressing on a Prior Platinum-Based Regimen
大会发言：韩宝惠教授 上海交通大学附属胸科医院
Mini oral session
专场：Gastrointestinal tumours, non-colorectal
LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First Results of the Phase 3 ORIENT-15 study
大会发言：沈琳教授 北京大学肿瘤医院
LBA53 - Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase 3 study
大会发言：徐建明教授 解放军总医院第五医学中心
1373MO - JUPITER-06: A Randomized, Double-blind, Phase 3 Study of Toripalimab versus Placebo In Combination with First-Line Chemotherapy for Treatment Naive Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
大会发言：徐瑞华教授 中山大学肿瘤防治中心
专场：Supportive and palliative care
LBA64 - Olanzapine, an Alternative to Dexamethasone for Preventing Nausea and Vomiting Induced by Cisplatin-Based Doublet Highly Emetogenic Chemotherapy: A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase 3 Clinical Trial
大会发言：刘志刚教授 中山大学附属第五医院
专场：Breast cancer, metastatic
228MO - PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
大会发言：徐兵河教授 中国医学科学院肿瘤医院
专场：Non-metastatic NSCLC and other thoracic malignancies
LBA43 - GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase 3 study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
大会发言：吴一龙教授 广东省人民医院，广东省肺癌研究所
专场：Haematological malignancies
828MO - Exonic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma
大会发言：李珊珊医师 中山大学附属第六医院
830MO - Integrated Driver Mutations Profile of Chinese NK/T Cell Lymphoma
大会发言：Ting-zhi Liu (Guangzhou, China)
831MO - Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
大会发言：石远凯教授 中国医学科学院肿瘤医院
专场：Basic science
4MO - Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models
大会发言：Lei Yin (Beijing, China)
更多详情请至官网查看：https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal/session/calendar
本文根据官方日程仅统计“Proffered Paper session” 以及“Mini oral session”中国专家报告内容，如有遗漏或补充请留言或联系肿瘤资讯-小编，微信号：oncologynews。
排版编辑：Amy
苏公网安备32059002004080号
